| Item Type | Name |
|
Concept
|
Clinical Protocols
|
|
Concept
|
Pharmacology, Clinical
|
|
Concept
|
Research Personnel
|
|
Concept
|
Research Support as Topic
|
|
Concept
|
Research
|
|
Concept
|
Clinical Trials, Phase I as Topic
|
|
Concept
|
Ethics, Research
|
|
Concept
|
Clinical Trials, Phase II as Topic
|
|
Concept
|
Decision Support Systems, Clinical
|
|
Concept
|
Empirical Research
|
|
Concept
|
Research Design
|
|
Concept
|
Biomedical Research
|
|
Concept
|
Clinical Medicine
|
|
Concept
|
Clinical Trials, Phase III as Topic
|
|
Concept
|
Comparative Effectiveness Research
|
|
Concept
|
Ethics Committees, Research
|
|
Concept
|
Clinical Trials as Topic
|
|
Concept
|
Research Subjects
|
|
Academic Article
|
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
|
Academic Article
|
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
|
|
Academic Article
|
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.
|
|
Academic Article
|
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
|
|
Academic Article
|
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
|
|
Academic Article
|
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
|
|
Academic Article
|
Data modifications to phase I study of suramin.
|
|
Academic Article
|
New phase I trial methodology.
|
|
Academic Article
|
Learning from our patients: one participant's impact on clinical trial research and informed consent.
|
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
|
|
Academic Article
|
Promising new agents in oncologic treatment.
|
|
Academic Article
|
Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
|
|
Academic Article
|
Clinical pharmacology of camptothecins.
|
|
Academic Article
|
Development of target-based antineoplastic agents.
|
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
|
Academic Article
|
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
|
|
Academic Article
|
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.
|
|
Academic Article
|
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
|
|
Academic Article
|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
|
|
Academic Article
|
Laboratory and clinical studies of biochemical modulation by hydroxyurea.
|
|
Academic Article
|
Endostatin: are the 2 years up yet?
|
|
Academic Article
|
Conflict-of-interest policies.
|
|
Academic Article
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
|
Academic Article
|
Troxacitabine in patients with refractory leukemia.
|
|
Academic Article
|
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
|
Academic Article
|
Pharmacogenomics: road to anticancer therapeutics nirvana?
|
|
Academic Article
|
Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs.
|
|
Academic Article
|
Clinical trial designs for cytostatic agents.
|
|
Academic Article
|
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
|
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
|
Academic Article
|
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
|
|
Academic Article
|
Pharmacokinetic variability of anticancer agents.
|
|
Academic Article
|
Phase II oncology trials: let's be positive.
|
|
Academic Article
|
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
|
|
Academic Article
|
From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.
|
|
Academic Article
|
Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
|
|
Academic Article
|
Finding the right dose.
|
|
Academic Article
|
Pharmacogenomics: challenges and opportunities.
|
|
Academic Article
|
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
|
|
Academic Article
|
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
|
|
Academic Article
|
The pharmacogenetics research network: from SNP discovery to clinical drug response.
|
|
Academic Article
|
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
|
|
Academic Article
|
Interpreting P values in pharmacogenetic studies: a call for process and perspective.
|
|
Academic Article
|
The value meal: how to save $1,700 per month or more on lapatinib.
|
|
Academic Article
|
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration.
|
|
Academic Article
|
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
|
|
Academic Article
|
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
|
|
Academic Article
|
Biomarkers in early cancer drug development: limited utility.
|
|
Academic Article
|
EGFR pharmacogenomics: the story continues to mutate and evolve.
|
|
Academic Article
|
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
|
|
Academic Article
|
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
|
|
Academic Article
|
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
|
|
Academic Article
|
Vascular endothelial growth factor pathway.
|
|
Academic Article
|
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
|
|
Academic Article
|
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
|
|
Academic Article
|
Evaluating the activity of temsirolimus in neuroendocrine cancer.
|
|
Academic Article
|
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
|
|
Academic Article
|
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
|
|
Academic Article
|
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
|
|
Academic Article
|
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?
|
|
Academic Article
|
Recommended changes to oncology clinical trial design: revolution or evolution?
|
|
Academic Article
|
The investigational drug steering committee.
|
|
Academic Article
|
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
|
|
Academic Article
|
Why RECIST works and why it should stay--reply to counterpoint.
|
|
Academic Article
|
Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.
|
|
Academic Article
|
Nonprofit biomedical companies.
|
|
Academic Article
|
Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia.
|
|
Academic Article
|
Optimising the design of phase II oncology trials: the importance of randomisation.
|
|
Academic Article
|
Prognostic factors for survival in patients treated in phase I clinical trials.
|
|
Academic Article
|
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions.
|
|
Academic Article
|
Resampling phase III data to assess phase II trial designs and endpoints.
|
|
Academic Article
|
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
|
|
Academic Article
|
A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
|
|
Academic Article
|
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
|
Academic Article
|
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
|
|
Academic Article
|
Pharmacogenomics: will the promise be fulfilled?
|
|
Academic Article
|
Randomized phase II trials: a long-term investment with promising returns.
|
|
Academic Article
|
Value-based insurance design: aligning incentives, benefits, and evidence in oncology.
|
|
Academic Article
|
Pushing the envelope: informed consent in phase I trials.
|
|
Academic Article
|
Pharmacogenomics and patient care: one size does not fit all.
|
|
Academic Article
|
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
|
|
Academic Article
|
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
|
|
Academic Article
|
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
|
|
Academic Article
|
Pharmacogenetics and pharmacogenomics of anticancer agents.
|
|
Academic Article
|
Dose-escalation models for combination phase I trials in oncology.
|
|
Academic Article
|
Analysis of the yield of phase II combination therapy trials in medical oncology.
|
|
Academic Article
|
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?
|
|
Academic Article
|
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.
|
|
Academic Article
|
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
|
|
Academic Article
|
Perceptions of cancer patients and their physicians involved in phase I trials.
|
|
Academic Article
|
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.
|
|
Academic Article
|
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
|
|
Academic Article
|
Drug combinations: dangerous liaisons or great expectations?
|
|
Academic Article
|
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
|
|
Academic Article
|
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
|
|
Academic Article
|
Measuring response in a post-RECIST world: from black and white to shades of grey.
|
|
Academic Article
|
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
|
|
Academic Article
|
Pharmacogenetic pathway analysis of irinotecan.
|
|
Academic Article
|
Opportunities and challenges in the development of experimental drug combinations for cancer.
|
|
Academic Article
|
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
|
|
Academic Article
|
Cancer pharmacogenomics: strategies and challenges.
|
|
Academic Article
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
|
Academic Article
|
Time to tumor growth: a model end point and new metric system for oncology clinical trials.
|
|
Academic Article
|
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
|
|
Academic Article
|
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
|
Academic Article
|
Targeted therapies: redefining the primary objective of phase I oncology trials.
|
|
Academic Article
|
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
|
|
Academic Article
|
Tumour heterogeneity in the clinic.
|
|
Academic Article
|
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.
|
|
Academic Article
|
Incorporating biomarkers into drug labeling.
|
|
Academic Article
|
Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.
|
|
Academic Article
|
Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project".
|
|
Academic Article
|
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
|
|
Academic Article
|
The impact of industry on oncology research and practice.
|
|
Academic Article
|
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.
|
|
Academic Article
|
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).
|
|
Academic Article
|
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
|
Academic Article
|
Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.
|
|
Academic Article
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
|
|
Academic Article
|
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
|
|
Academic Article
|
Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.
|
|
Academic Article
|
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.
|
|
Academic Article
|
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
|
|
Academic Article
|
Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.
|
|
Academic Article
|
Disease-drug database for pharmacogenomic-based prescribing.
|
|
Academic Article
|
Interferon Alfa-2b Antibodies and Clinical Resistance in a Patient with Hairy Cell Leukemia.
|
|
Academic Article
|
Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.
|
|
Academic Article
|
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
|
|
Academic Article
|
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program.
|
|
Academic Article
|
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
|
|
Academic Article
|
Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.
|
|
Academic Article
|
Burdensome Research Procedures in Trials: Why Less Is More.
|
|
Academic Article
|
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.
|
|
Academic Article
|
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
|
|
Academic Article
|
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
|
|
Academic Article
|
Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?
|
|
Academic Article
|
Essential Characteristics of Pharmacogenomics Study Publications.
|
|
Academic Article
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
|
|
Academic Article
|
Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system.
|
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
|
Academic Article
|
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
|
|
Academic Article
|
Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study.
|
|
Academic Article
|
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
|
|
Academic Article
|
Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty.
|
|
Academic Article
|
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.
|
|
Academic Article
|
Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement.
|
|
Academic Article
|
The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care.
|
|
Academic Article
|
Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients.
|
|
Academic Article
|
Pharmacogenomic-Based Decision Support to Predict Adherence to Medications.
|
|
Academic Article
|
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
|
|
Academic Article
|
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter.
|
|
Academic Article
|
Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.
|
|
Academic Article
|
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
|
|
Academic Article
|
Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
|
|
Academic Article
|
The Right Dose: From Phase I to Clinical Practice.
|
|
Academic Article
|
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.
|
|
Academic Article
|
Creation of a pharmacogenomics patient portal complementary to an existing institutional provider-facing clinical decision support system.
|
|
Academic Article
|
Designing Dose-Finding Phase I Clinical Trials: Top Questions That Should Be Discussed With Your Clinical Pharmacologist.
|
|
Academic Article
|
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
|
|
Academic Article
|
An Expanded Role for IRBs in the Oversight of Research Biopsies.
|
|
Academic Article
|
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
|
|
Concept
|
Clinical Decision-Making
|
|
Academic Article
|
Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?
|
|
Academic Article
|
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).
|